Abstract: Objective To evaluate the quality of randomized controlled trials (RCTs) for Fermentative Cordycepic Fungal Powder on chronic obstructive pulmonary disease (COPD) and interstitial lung diseases (ILDs). Methods The electronic databases of Medline via PubMed, Cochrane Library, China Biology Medicine disc (CBM), China National Knowledge Infrastructure(CNKI), WANFANG data base and VIP were searched for human randomized controlled trial (RCT) and quasi-RCT by using the key words Fermentative Cordycepic Fungal Powder, COPD and ILDs. The quality was assessed by using recommended criteria by Cochrane Collaboration. The quality of each report was assessed by using the consolidated standards of reporting trials (CONSORT) checklist. Professional assessment of diagnostic criteria, interventions, and outcome indicator setting were accorded with clinical guidelines. Results Totally 126 were met the inclusion criteria, among them, 112 were related to COPD, and 14 were related to interstitial lung disease or silicosis with COPD. The quality of the research methodology (COPD correction rate 0%-35.7%; ILDs correction rate 9.1%-18.2%) and the quality of the reports of the reports in this group were defective and need to be urgently improved. The selected literature also has great defects in the confirmation of the diagnosis (COPD rational rate 42.3%;ILDs rational rate 78.6%), the setting up of treatment plans (COPD rational rate 28.8%;ILDs rational rate 14.3%), the parameters using to evaluate efficacy (COPD rational rate 50%;ILDs rational rate 64.3%) were also need to be improved. Conclusion The current literatures don't warrant the efficacy of the comprehensive treatment with fenebtable on the improvement of COPD and ILDs for the lack of decentness among current studies, and well-designed researches are needed to determine the aforementioned clinical significance.

Key words: chronic obstructive pulmonary disease, interstitial lung diseases, fermentative cordycepic fungal powder, quality evaluation